

## Special Issue

# Chronic Viral Infections and Cancer: Openings for Vaccines and Cure

### Message from the Guest Editors

Specific human virus infections are the primary cause of cancer. These viral infections are estimated to lead to about 10% of the global cancer burden. Key oncogenic viruses include Hepatitis B virus (HBV), Human papillomaviruses (HPV), Hepatitis C virus (HCV), Epstein-Barr virus (EBV), Human immunodeficiency virus type 1 (HIV-1), Human T-cell leukemia virus type 1 (HTLV-1), and Human herpes virus 8 (HHV-8).

This Special Issue welcomes submissions of experimental papers, short communications, reviews, and activity reports focusing on the above issues. Cordial invitation to submit is addressed to the speakers of the international online conference “Chronic viral infections and cancer, openings for vaccines and cure” VIRCAN2024 held at Riga Stradins University, Riga, Latvia, November 21–22, 2024 (<https://www.rsu.lv/en/vircan2024-conference>) and VIRCAN2026 planned at Riga Stradins University, Riga, Latvia, in November 2026.

---

### Guest Editors

Dr. Maria G. Isaguliantis

Institute of Microbiology and Virology, Riga Stradins University, Riga, Latvia

Dr. Karl Ljungberg

International Vaccine Institute (IVI), Stockholm, Sweden

---

### Deadline for manuscript submissions

31 January 2027



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/232365](https://mdpi.com/si/232365)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).